MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte (NASDAQ: MXCT) announced the launch of CHANGE-seq-BE™ and ONE-seq-BE™, new off-target nomination assays for adenine and cytosine base editors, offered through its SeQure™ gene editing risk assessment service.

Rhea-AI Summary

MaxCyte (NASDAQ: MXCT) announced the launch of CHANGE-seq-BE™ and ONE-seq-BE™, new off-target nomination assays for adenine and cytosine base editors, offered through its SeQure™ gene editing risk assessment service.

CHANGE-seq-BE is described as a sensitive, unbiased biochemical method to nominate off-target sites for base editors, while ONE-seq-BE is presented as the only base-editor nomination assay that provides full visibility into population-specific genetic variants that may influence off-target activity. SeQure integrates outputs from these orthogonal assays and existing confirmation assays for quantitative off-target editing and structural variation detection, helping therapeutic developers assess off-target risks in relevant cell and tissue contexts and align with evolving regulatory expectations, including recent FDA guidance on off-target editing and genome safety.

Argus Aug 19 session 9 alerts

+9.45% close to close 1.6x rel. volume Open Argus

Details

Market move: MXCT +9.45% in the Aug 19 session. off-target assay launch

+4.5% Peak in 5 hr 59 min

$143.46M Market Cap

On Aug 19, the day this news came out, MXCT closed 9.45% above the previous close. Argus tracked a peak move of +4.5% during that session. Our momentum scanner recorded 9 alerts for this stock that day. Relative volume reached 1.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 19 session.

Key Figures

Announcement date: Aug. 19, 2026 Company history: More than 25 years

Announcement date

Aug. 19, 2026

Publication date

Company history

More than 25 years

MaxCyte company description

Historical Context

5 past events · Latest: Aug 12

5 events

1. Aug 12

   Q2 earnings report

   24h Move

   +9.4%

   Loss narrowed, guidance was reiterated, and the Genentech partnership was highlighted.

2. Jul 21

   Genentech partnership

   24h Move

   +5.1%

   Multi-platform license partnership expanded access to MaxCyte technology.

3. Jul 15

   Q2 earnings date

   24h Move

   -4.9%

   The company scheduled its Q2 financial results and conference call.

4. May 12

   Q1 earnings report

   24h Move

   +24.1%

   Guidance was reiterated, losses narrowed, and a share repurchase was authorized.

5. Apr 29

   Q1 earnings date

   24h Move

   +7.6%

   The company scheduled its Q1 financial results and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

off-target nomination assays, adenine base editors, cytosine base editors, orthogonal assays

4 terms

off-target nomination assays technical

"announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays"

Laboratory tests that search for unintended biological targets affected by a therapy or genome-editing tool, producing a prioritized list of possible off-target sites for follow-up study. Think of them as a safety “spell-check” that flags where a drug or gene-editing agent might interact with the wrong molecule or gene; the results matter to investors because they inform safety profiles, regulatory scrutiny, development timelines, and the likelihood of costly fixes or clinical delays.

adenine base editors technical

"offering sensitive nomination of off-target sites for adenine and cytosine base editors"

Adenine base editors are laboratory gene‑editing tools that change a single DNA letter from adenine (A) to guanine (G) without cutting the DNA strand, like using a precise find‑and‑replace function instead of a pair of scissors. They matter to investors because they enable targeted corrections of genetic mutations with potentially fewer side effects than older techniques, affecting the valuation and risk of companies developing genetic therapies and related technologies.

cytosine base editors technical

"offering sensitive nomination of off-target sites for adenine and cytosine base editors"

A cytosine base editor is a gene‑editing tool that chemically converts one DNA letter, cytosine (C), into another, typically thymine (T), at a specific spot in the genome without cutting both strands of DNA. Like a targeted find‑and‑replace that edits a single letter in an instruction manual, it lets researchers change a genetic instruction precisely, which matters to investors because it underpins drug development pipelines, licensing deals, safety and regulatory risk assessments, and the commercial value of biotech programs.

orthogonal assays technical

"with a growing emphasis on orthogonal assays, assay sensitivity, and modality-appropriate methods"

Orthogonal assays are independent laboratory tests that use different methods to measure the same biological effect or signal, so one test verifies the findings of another — like checking a measurement with both a ruler and a laser. For investors, they matter because independent confirmation reduces the chance of false positives, strengthens the credibility of scientific claims, and lowers technical and regulatory risk that can affect a program's timeline and value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte’s SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).

SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and to prioritize regions for confirmation assays. CHANGE-seq-BE is a sensitive, unbiased biochemical off-target nomination method for base editors, and ONE-seq-BE is the only nomination assay for base editors that provides full visibility of population-specific genetic variants that may impact off-target activity. By combining these two assays, MaxCyte is uniquely positioned as a single-source provider of orthogonal nomination assays for base editors. Together with SeQure’s existing confirmation assays for quantitative off-target editing measurement and structural variation detection, therapeutic developers can confidently assess off-target risks in the relevant cell and tissue context. This is especially important as developers work to align with evolving regulatory expectations – including recent FDA guidance on off-target editing and genome safety – with a growing emphasis on orthogonal assays, assay sensitivity, and modality-appropriate methods.

Maher Masoud, President and CEO at MaxCyte, commented: “Base editors are creating new opportunities for therapeutic development, while also requiring safety assessment strategies that reflect their mechanisms of action. The addition of CHANGE-seq-BE and ONE-seq-BE to our SeQure services gives developers access to sensitive, orthogonal off-target assessment capabilities that can help them to better understand and mitigate off-target risk, building stronger data packages for clinical development.”

For more information about MaxCyte’s SeQure services, please visit maxcyte.com/sequre.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. 

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

MaxCyte Contacts:

Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060

Editorial contact for further information or follow-up:
Sarah Ballard at kdm communications limited, St Neots, UK
Tel. +44 (0)1480 405333   Fax: +44 (0)1480 477833
email ideas@kdm-communications.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MaxCyte (NASDAQ: MXCT) announce on August 19, 2026 about CHANGE-seq-BE and ONE-seq-BE?

MaxCyte announced the launch of its CHANGE-seq-BE and ONE-seq-BE off-target nomination assays for base editors. According to MaxCyte, these assays are delivered through its SeQure service and focus on off-target assessment for adenine and cytosine base editors in therapeutic development.

How do MaxCyte’s CHANGE-seq-BE and ONE-seq-BE assays improve off-target assessment for base editors in MXCT’s SeQure service?

The assays provide sensitive nomination of off-target sites for adenine and cytosine base editors. According to MaxCyte, CHANGE-seq-BE offers an unbiased biochemical approach, while ONE-seq-BE adds visibility into population-specific genetic variants impacting off-target activity within the SeQure integrated reporting framework.

What is unique about the ONE-seq-BE assay launched by MaxCyte (MXCT) in 2026?

ONE-seq-BE is described as the only base editor nomination assay that reveals population-specific genetic variants influencing off-target activity. According to MaxCyte, this capability helps therapeutic developers understand how genetic diversity may affect off-target risks when evaluating base editing strategies.

How do CHANGE-seq-BE and ONE-seq-BE fit into MaxCyte’s SeQure gene editing risk assessment platform for MXCT investors?

The assays expand SeQure’s orthogonal nomination capabilities for base editors and link to existing confirmation assays for quantitative off-target measurement and structural variation detection. According to MaxCyte, this integration supports comprehensive off-target risk assessment in relevant cell and tissue contexts.

How do MaxCyte’s new CHANGE-seq-BE and ONE-seq-BE assays relate to evolving FDA guidance on genome editing safety?

MaxCyte states the assays help developers align with evolving FDA guidance emphasizing orthogonal assays, sensitivity, and modality-appropriate methods. According to MaxCyte, combining these assays supports stronger off-target data packages for clinical development of genome editing therapies.

What types of genome editing tools are targeted by MaxCyte’s CHANGE-seq-BE and ONE-seq-BE assays for MXCT stakeholders?

The assays focus on off-target nomination for adenine base editors (ABEs) and cytosine base editors (CBEs). According to MaxCyte, these tools support developers using base editing technologies to create next-generation cell and gene therapies while rigorously assessing off-target editing risks.